 |
245 Diseases |  |
54 Trials |
|
54 Trials |  |
1419 News |  |
| «12...4567891011121314...2021» |
- [VIRTUAL] MORBIDITY AND MORTALITY OF T- CELL LYMPHOMAS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2816;
In our population, a higher OS and DFS are reported compared to other series. It may be because the transplant was performed at earlier stage; fewer lines of treatments, low ECOG and IPI and complete response before ASCT.
- [VIRTUAL] IMPACT OF AHSCT ON FERTILITY IN MULTIPLE SCLEROSIS PATIENTS (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2176;
Our data confirm that AHSCT deeply affects gonadal function in females, with more severe impact among older women. It should be pointed out that most of the patients had received cytotoxic treatments before transplant that could have affected gonadal function at baseline and/or might have enhanced AHSCT-related toxicity.
- [VIRTUAL] IMPACT OF AHSCT ON FERTILITY IN MULTIPLE SCLEROSIS PATIENTS (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2175;
Our data confirm that AHSCT deeply affects gonadal function in females, with more severe impact among older women. It should be pointed out that most of the patients had received cytotoxic treatments before transplant that could have affected gonadal function at baseline and/or might have enhanced AHSCT-related toxicity.
- [VIRTUAL] IMPACT OF AHSCT ON FERTILITY IN MULTIPLE SCLEROSIS PATIENTS (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2174;
Our data confirm that AHSCT deeply affects gonadal function in females, with more severe impact among older women. It should be pointed out that most of the patients had received cytotoxic treatments before transplant that could have affected gonadal function at baseline and/or might have enhanced AHSCT-related toxicity.
- [VIRTUAL] IMPACT OF AHSCT ON FERTILITY IN MULTIPLE SCLEROSIS PATIENTS (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2173;
Our data confirm that AHSCT deeply affects gonadal function in females, with more severe impact among older women. It should be pointed out that most of the patients had received cytotoxic treatments before transplant that could have affected gonadal function at baseline and/or might have enhanced AHSCT-related toxicity.
- bendamustine / Generic mfg.
[VIRTUAL] BENDAMUSTINE-BASED CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT IMPROVES OUTCOMES IN PATIENTS WITH ELAPSED-REFRACTORY NON-HODGKIN LYMPHOMA (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1968;
It should be pointed out that most of the patients had received cytotoxic treatments before transplant that could have affected gonadal function at baseline and/or might have enhanced AHSCT-related toxicity. The substitution of carmustine to bendamustine in the conditioning regimen prior to aHCT improves outcomes in patients with rR-NHL and should be considered a new standard.
- bendamustine / Generic mfg.
[VIRTUAL] BENDAMUSTINE-BASED CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT IMPROVES OUTCOMES IN PATIENTS WITH ELAPSED-REFRACTORY NON-HODGKIN LYMPHOMA (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1967;
The substitution of carmustine to bendamustine in the conditioning regimen prior to aHCT improves outcomes in patients with rR-NHL and should be considered a new standard. The substitution of carmustine to bendamustine in the conditioning regimen prior to aHCT improves outcomes in patients with rR-NHL and should be considered a new standard.
- bendamustine / Generic mfg.
[VIRTUAL] BENDAMUSTINE-BASED CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT IMPROVES OUTCOMES IN PATIENTS WITH ELAPSED-REFRACTORY NON-HODGKIN LYMPHOMA (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1966;
The substitution of carmustine to bendamustine in the conditioning regimen prior to aHCT improves outcomes in patients with rR-NHL and should be considered a new standard. The substitution of carmustine to bendamustine in the conditioning regimen prior to aHCT improves outcomes in patients with rR-NHL and should be considered a new standard.
- bendamustine / Generic mfg.
[VIRTUAL] BENDAMUSTINE-BASED CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT IMPROVES OUTCOMES IN PATIENTS WITH ELAPSED-REFRACTORY NON-HODGKIN LYMPHOMA (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1965;
The substitution of carmustine to bendamustine in the conditioning regimen prior to aHCT improves outcomes in patients with rR-NHL and should be considered a new standard. The substitution of carmustine to bendamustine in the conditioning regimen prior to aHCT improves outcomes in patients with rR-NHL and should be considered a new standard.
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Trial completion date, Trial primary completion date, Combination therapy: Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma (clinicaltrials.gov) - Feb 2, 2021
P1, N=30, Recruiting, Sponsor: Case Comprehensive Cancer Center
The substitution of carmustine to bendamustine in the conditioning regimen prior to aHCT improves outcomes in patients with rR-NHL and should be considered a new standard. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Jul 2021
- | carmustine / Generic mfg.
New P2 trial: Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases (clinicaltrials.gov) - Jan 27, 2021
P2, N=28, Not yet recruiting, Sponsor: Thomas Jefferson University
- | irinotecan / Generic mfg.
Biomarker, Journal: Evaluation of Glycolytic Response to Multiple Classes of Anti-glioblastoma Drugs by Noninvasive Measurement of Pyruvate Kinase M2 Using [F]DASA-23. (Pubmed Central) - Jan 23, 2021
P1
These proof of principle studies emphasize the superiority of [F]DASA-23 to [F]FDG in detecting the glycolytic response of GBM to multiple classes of anti-neoplastic drugs in cell culture. A clinical trial evaluating the diagnostic utility of [F]DASA-23 PET in GBM patients (NCT03539731) is ongoing.
- || Mustargen (mechlorethamine) / Recordati
Enrollment open, BRCA Biomarker, Metastases: SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells (clinicaltrials.gov) - Jan 14, 2021
P1, N=10, Recruiting, Sponsor: General Oncology, Inc.
A clinical trial evaluating the diagnostic utility of [F]DASA-23 PET in GBM patients (NCT03539731) is ongoing. Not yet recruiting --> Recruiting
- | Journal: Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas. (Pubmed Central) - Jan 14, 2021
At a median follow-up duration of 49.3 months, the estimated 3-year progression-free survival and overall survival were 55.2% and 68.2% in all patients. The BuEAM high-dose regimen for ASCT was well tolerated and seemed to be effective in patients with T-cell lymphomas.
- || Zinbryta (daclizumab) / Biogen, AbbVie
Clinical, Journal: Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma. (Pubmed Central) - Jan 13, 2021
Furthermore, the strong β radiation killed normal cells in the tumor microenvironment that nurtured the malignant cells in the lymphomatous mass. The present study supports expanded analysis of Y-daclizumab as part of the regimen of ASCT in patients with refractory and relapsed HL.
- [VIRTUAL] Flubutbi Versus BEAM As the Conditioning Regimen before Autologous Hematopoietic Stem Cell Transplantation in Lymphoid Malignancies () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1322;
Our study is limited by its retrospective nature and relatively small population. The choice of conditioning regimen should depend on physician and institutional experience, taking into account different toxicity profiles and patient characteristics.
- [VIRTUAL] Flubutbi Versus BEAM As the Conditioning Regimen before Autologous Hematopoietic Stem Cell Transplantation in Lymphoid Malignancies () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1321;
Our study is limited by its retrospective nature and relatively small population. The choice of conditioning regimen should depend on physician and institutional experience, taking into account different toxicity profiles and patient characteristics.
- [VIRTUAL] Flubutbi Versus BEAM As the Conditioning Regimen before Autologous Hematopoietic Stem Cell Transplantation in Lymphoid Malignancies () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1320;
Our study is limited by its retrospective nature and relatively small population. The choice of conditioning regimen should depend on physician and institutional experience, taking into account different toxicity profiles and patient characteristics.
- [VIRTUAL] Flubutbi Versus BEAM As the Conditioning Regimen before Autologous Hematopoietic Stem Cell Transplantation in Lymphoid Malignancies () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1319;
Our study is limited by its retrospective nature and relatively small population. The choice of conditioning regimen should depend on physician and institutional experience, taking into account different toxicity profiles and patient characteristics.
- [VIRTUAL] Flubutbi Versus BEAM As the Conditioning Regimen before Autologous Hematopoietic Stem Cell Transplantation in Lymphoid Malignancies () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1318;
Our study is limited by its retrospective nature and relatively small population. The choice of conditioning regimen should depend on physician and institutional experience, taking into account different toxicity profiles and patient characteristics.
- carmustine / Generic mfg., bendamustine / Generic mfg., Bioprofarma
[VIRTUAL] Substitution of Carmustine for Bendamustine in the Transplant Conditioning Regimen Improves Survival in Relapsed/Refractory Lymphoma Patients. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1272;
The choice of conditioning regimen should depend on physician and institutional experience, taking into account different toxicity profiles and patient characteristics. The substitution of carmustine for bendamustine in the conditioning prior to aHCT results in better lymphoma-associated outcome and should be considered as a new standard.
- carmustine / Generic mfg., bendamustine / Generic mfg., Bioprofarma
[VIRTUAL] Substitution of Carmustine for Bendamustine in the Transplant Conditioning Regimen Improves Survival in Relapsed/Refractory Lymphoma Patients. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1271;
The substitution of carmustine for bendamustine in the conditioning prior to aHCT results in better lymphoma-associated outcome and should be considered as a new standard. The substitution of carmustine for bendamustine in the conditioning prior to aHCT results in better lymphoma-associated outcome and should be considered as a new standard.
- carmustine / Generic mfg., bendamustine / Generic mfg., Bioprofarma
[VIRTUAL] Substitution of Carmustine for Bendamustine in the Transplant Conditioning Regimen Improves Survival in Relapsed/Refractory Lymphoma Patients. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1270;
The substitution of carmustine for bendamustine in the conditioning prior to aHCT results in better lymphoma-associated outcome and should be considered as a new standard. The substitution of carmustine for bendamustine in the conditioning prior to aHCT results in better lymphoma-associated outcome and should be considered as a new standard.
- carmustine / Generic mfg., bendamustine / Generic mfg., Bioprofarma
[VIRTUAL] Substitution of Carmustine for Bendamustine in the Transplant Conditioning Regimen Improves Survival in Relapsed/Refractory Lymphoma Patients. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1269;
The substitution of carmustine for bendamustine in the conditioning prior to aHCT results in better lymphoma-associated outcome and should be considered as a new standard. The substitution of carmustine for bendamustine in the conditioning prior to aHCT results in better lymphoma-associated outcome and should be considered as a new standard.
- carmustine / Generic mfg., bendamustine / Generic mfg., Bioprofarma
[VIRTUAL] Substitution of Carmustine for Bendamustine in the Transplant Conditioning Regimen Improves Survival in Relapsed/Refractory Lymphoma Patients. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1268;
The substitution of carmustine for bendamustine in the conditioning prior to aHCT results in better lymphoma-associated outcome and should be considered as a new standard. The substitution of carmustine for bendamustine in the conditioning prior to aHCT results in better lymphoma-associated outcome and should be considered as a new standard.
- | Journal: Resolution of Chronic Immune Thrombocytopenia Purpura after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma. (Pubmed Central) - Jan 5, 2021
This is the first clinical case in the world demonstrating that high-dose BEAM chemotherapy conditioned autologous HSCT could cure chronic ITP while successfully managing refractory/relapse DLBCL. The clinical hematology professionals and the patients will benefit from our experience in managing severe thrombocytopenia while conducting high-dose chemotherapy conditioning and autologous HSCT for DLBCL.
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jan 5, 2021
P1, N=15, Recruiting, Sponsor: Washington University School of Medicine
The clinical hematology professionals and the patients will benefit from our experience in managing severe thrombocytopenia while conducting high-dose chemotherapy conditioning and autologous HSCT for DLBCL. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2020 --> Dec 2021
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Autologous Hematopoietic Cell Transplant Outcomes after Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma () - Dec 20, 2020 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_459;
P2
- | paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Journal: Prediction of the permeability of antineoplastic agents through nitrile medical gloves by zone classification based on their physicochemical properties. (Pubmed Central) - Dec 10, 2020
The permeation risk of antineoplastic agents through nitrile medical gloves within the actual continuous wearing time in clinical settings could be predicted using MW and LogP values. We believe that the proposed zone classification of antineoplastic agents will be a useful tool for predicting the permeation risk of antineoplastic agents through medical gloves.
- || cyclophosphamide intravenous / Generic mfg., gemcitabine / Generic mfg.
Clinical, Journal: Efficacy of Gemcitabine on Intracranial Erlich Tumor and its Determinants. (Pubmed Central) - Nov 25, 2020
On intramuscular tumor model, gemcitabine showed significant antitumor effect at both 25 and 2.5 mg/kg, indicating a wide range of therapeutic doses of this drug. Pronounced therapeutic effect of gemcitabine on intracranial tumor most likely is due to the small but sufficient concentration of the drug that overcomes the BBB.
- | Starasid (cytarabine ocfosfate) / Nippon Kayaku
Trial termination: Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies (clinicaltrials.gov) - Nov 23, 2020
P1, N=3, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
Pronounced therapeutic effect of gemcitabine on intracranial tumor most likely is due to the small but sufficient concentration of the drug that overcomes the BBB. Active, not recruiting --> Terminated; Closed early due to lack of funding
- | Ninlaro (ixazomib) / Takeda
Trial completion, Trial completion date: Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma (clinicaltrials.gov) - Nov 23, 2020
P1, N=11, Completed, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Terminated; Closed early due to lack of funding Active, not recruiting --> Completed | Trial completion date: Jul 2021 --> Sep 2020
- | carmustine / Generic mfg.
Retrospective data, Journal: Implantation of carmustine wafers (Gliadel) for high-grade glioma treatment. A 9-year nationwide retrospective study. (Pubmed Central) - Nov 22, 2020
OS after CW implantation is significantly variable as influenced by many factors such as age, gender or recurrent disease but not by post-operative complications. Compare to previous results, CW may increase the OS and this effect seems more pronounced when adjuvant RT/TMZ is given.
- Mustargen (mechlorethamine) / Recordati
Phase classification, BRCA Biomarker, Metastases: SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells (clinicaltrials.gov) - Nov 16, 2020
P1, N=10, Not yet recruiting, Sponsor: General Oncology, Inc.
Compare to previous results, CW may increase the OS and this effect seems more pronounced when adjuvant RT/TMZ is given. Phase classification: P2 --> P1
- | carmustine / Generic mfg.
Journal: Multi-layered core-sheath fiber membranes for controlled drug release in the local treatment of brain tumor. (Pubmed Central) - Nov 12, 2020
A novel core-sheath fiber loaded with the drug carmustine (BCNU) was evaluated in an in vivo brain tumor model...Drug delivery with coaxial core-sheath structures benefits from high drug loading, controlled long-term release kinetics, and slow polymer degradation. This represents a promising evolution for the current treatment of GBM.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] A Systematic Review of High Dose Chemotherapy with Autologous Transplantation in Secondary CNS Lymphoma () - Nov 5, 2020 - Abstract #ASH2020ASH_5441;
However, the data at present is limited to few phase 2 trials with some being displayed collectively with data of primary CNS lymphoma patients. There is an increased need to carry out randomized phase 3 trials exclusively on SCNSL patients to better predict the efficacy and safety profile of HDT/ASCT in these patients.
- idarubicin hydrochloride / Generic mfg.
[VIRTUAL] Modified Beac Conditioning Regimen with Idarubicin Followed By Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective for Invasive B-Cell Non-Hodgkin's Lymphoma Patients () - Nov 5, 2020 - Abstract #ASH2020ASH_5437;
Multivariate analysis showed that AnnArbor staging, IPI score, lactate dehydrogenase (LDH) level, remission of disease, modified regimen were related with the prognosis. In conclusion, IEAC regimen was well tolerated and replacement with idarubicin could effectively prolong the survival of patients.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Efficacy of High Dose Chemotherapy with Autologous Transplantation for Primary CNS Lymphoma Treatment () - Nov 5, 2020 - Abstract #ASH2020ASH_5432;
Evidence is limited by mainly phase II non randomized data. Although, hematologic adverse effects due to HDT were observed on a widespread basis, transplant related mortality was however minimal.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Superiority of Thiotepa-Containing Conditioning Regimens in Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS) Undergoing Autologous Hematopoietic Cell Transplantation (autoHCT) (Channel 23 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_4405;
Extrapolating experience from systemic lymphomas, BEAM (BCNU/etoposide/cytarabine/melphalan) is also prescribed for PCNSL in the U.S. Using the Center for International Blood & Marrow Transplant Research (CIBMTR) registry, we compared outcomes for PCNSL patients undergoing autoHCT using the three most commonly employed conditioning regimens: TBC vs. TT-BCNU vs. BEAM...Variables considered in regression model include patient age, sex, race, performance status, HCT-comorbidity index (HCT-CI), rituximab use during conditioning, interval between diagnosis and HCT, and remission status...Adjusted 3-year PFS favored TBC and TT-BCNU over BEAM and suggest that use of BEAM should be discouraged in this specific setting. Whether TBC or TT-BCNU is the optimal conditioning regimen requires further inquiry in a prospective clinical trial.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_4138;
Conclusions : Upfront ASCT is associated with significantly improved and durable survival in patients with AITL. Receiving more than one prior line of therapy (transplant for relapsed AITL) and elevated LDH at transplant are associated with very poor prognosis, for which allogeneic transplant and alternative novel therapies should be further explored.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_4130;
Autologous transplant remains to be a good option as consolidation for patients with T-cell lymphoma, mostly in patients with first complete remission. While close to 40% of the patients experienced relapse after autologous transplant, additional therapies such as brentuximab vedotin or/and allogeneic transplant can provide long-term benefit for these patients.
- Polivy (polatuzumab vedotin) / Roche, Seagen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3855;
The phase II randomized controlled study (GO29365) showed PoV in combination with bendamustine and rituximab (BR) conferred an additional 22% complete response rate for relapsed/refractory DLBCL, compared with BR alone (40% vs. 18%)...Regarding combination therapies, 20 (62.5%) received BR, 5 (15.6%) had rituximab, 5 (15.6%) had rituximab/carmustine-containing regimens, and rituximab/gemcitabine-based ones were given to 4 (12.5%) patients...Conclusion As the third-line or above treatment for DLBCL in this study, the efficacy and safety associated with PoV-based therapies not only were encouraging but also helped bridge to transplants. The application of this monoclonal antibody-drug conjugate in future clinical trials for DLBCL is expected.
- CNCT19 / CASI, Juventas Cell Therapy, Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_2813;
More patients achieved sustained remission compared with those who received anti-CD19 CAR T-cell therapy alone. The preliminary results of this pilot study support further investigation of the combination of CAR T cellular immunotherapy with HDT/ASCT.
- | VBI-1901 / VBI Vaccines
Enrollment closed: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects (clinicaltrials.gov) - Nov 5, 2020
P1/2, N=38, Active, not recruiting, Sponsor: VBI Vaccines Inc.
The preliminary results of this pilot study support further investigation of the combination of CAR T cellular immunotherapy with HDT/ASCT. Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
[VIRTUAL] Treatment Outcomes of Midline Gliomas with H3K27 M: Our Barrow Neurological Institute Experience () - Oct 24, 2020 - Abstract #SNO2020SNO_1047;
This case series demonstrates that multiple treatment rounds with chemotherapy and radiation therapy may benefit patients, with bevacizumab/lomustine and surgery/carmustine appearing to lead to promising outcomes. Further research is needed to establish evidence-based protocols so quality of life and survival time in these patients may improve.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] MATRix regimen for newly diagnosed primary diffuse B-cell lymphoma of the central nervous system () - Oct 24, 2020 - Abstract #SNO2020SNO_767;
Patients without disease progression received carmustine 400 mg/sq m and thiotepa 4 X 5 mg/kg followed by autologous bone marrow transplantation...These preliminary data suggest that the MATRix regimen in safe and highly effective in the newly diagnosed setting. However, the high incidence of early death in patients over 70 y suggests that the regimen may be too toxic for elderly individuals.
- temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2) / Genenta Science
[VIRTUAL] AUTOLOGOUS CD34+ ENRICHED HEMATOPOIETIC PROGENITOR CELLS GENETICALLY MODIFIED FOR HUMAN INTERFERON-α2, ARE WELL TOLERATED & RAPIDLY ENGRAFT IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (TEM-GBM_001 STUDY) () - Oct 24, 2020 - Abstract #SNO2020SNO_456;
Disease progression has been confirmed in 3 patients who received Temferon. These preliminary results indicate feasibility of engrafting a pre-determined fraction of Temferon cells in the bone marrow of GBM patients without, so far, causing dose-limiting toxicity.
- | Jakafi (ruxolitinib) / Novartis, Incyte
New P1/2 trial: Ruxolitinib and Decitabine for High Risk Hematological Malignancies (clinicaltrials.gov) - Oct 8, 2020
P1/2, N=60, Recruiting, Sponsor: Chinese PLA General Hospital
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion date, Trial primary completion date: Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Oct 7, 2020
P2, N=101, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
These preliminary results indicate feasibility of engrafting a pre-determined fraction of Temferon cells in the bone marrow of GBM patients without, so far, causing dose-limiting toxicity. Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2020 --> Jul 2021
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Journal: An atypical presentation of primary central nervous system lymphoma: A case report. (Pubmed Central) - Oct 7, 2020
We report a patient with multifocal PCNSL involving the choroid plexus, who presented with abnormal gait and episodic confusion and memory loss. PCNSL should be considered in the differential diagnosis of acute encephalopathy among immunocompetent older individuals who have choroid plexus enhancing lesions.